Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SYNEBIO

Financiado

High-throughput combinatory drugs testing on in vitro 3D cells model platform

Drug combinations can lead to the discovery of novel drugs by increasing efficacy or lowering toxicity through synergy. This can boost existing drugs, rescue drug candidates, and accelerate drug discovery for yet poorly addressed... ver más

30/06/2024

ESPCI Paris

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

ESPCI Paris

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIO2014-59614-JIN DISEÑO DE DISPOSITIVOS DE ALTO RENDIMIENTO BASADO EN MICROSO... 204K€ Cerrado

PTQ2021-011961 Development of a novel drug screening platform to identify s... 115K€ Cerrado

3DCardiacHTS Bringing 3D cardiac tissues to high throughput for drug disc... 1M€ Cerrado

EQC2021-007516-P MIcroscopia de CRibado de Alto Contenido para el estudio de... 654K€ Cerrado

Easy SOFT Easy way to accelerate the scale-up of innovative soft devic... 75K€ Cerrado

POC-TDM Development of a point-of-care microfluidic device for Thera... 158K€ Cerrado

Duración del proyecto: 20 meses Fecha Inicio: 2022-10-07
Fecha Fin: 2024-06-30

Líder del proyecto

ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDU... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Drug combinations can lead to the discovery of novel drugs by increasing efficacy or lowering toxicity through synergy. This can boost existing drugs, rescue drug candidates, and accelerate drug discovery for yet poorly addressed diseases. However, predicting synergy is difficult, and finding synergies requires high-throughput screening (HTS) in advanced cell models. Current solutions propose either HTS in 2D cell cultures or low throughput assays in 3D cell cultures, but not both. On the basis of a technology developed in the ERC-funded AbioEvo project, we devised an innovative microfluidic platform for 3D culture and HTS of drug combinations. Miniaturization densifies routine 3D assays, resulting in a throughput increase of 10 to 100 times. Fluidic automation reduces liquid handling 500 times for a 100x100 drug library at a 10-point dose-response combinatorial screening. Furthermore, 3D culture models better predict later physiological responses, thus increasing the success probability of downstream drug development stages. We have shown dose-response measurements of 144 antibiotic combinations on bacteria on a single chip. In this POC, we aim to demonstrate the applicability of our technology to human cells and benchmark it based on existing screens for breast cancer cells. We will adapt the cell culture conditions and data analysis, perform market analysis, and examine industrialization feasibility. This will put us in a position to create a spin-off to reach the preclinical drug screening market and identify the most promising therapeutic areas. Indeed, the technology has the potential to screen for synergistic drug combinations at an earlier stage of the drug discovery process (thanks to miniaturization and automation) while providing a more reliable cellular response for later stages (thanks to 3D culture).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores